RecruitingNCT04929912
Electroporation for Cancer Treatment Real World Registry
Sponsor
Mirai Medical
Enrollment
1,000 participants
Start Date
Jun 24, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.
Eligibility
Inclusion Criteria4
- Any patient who has been treated using Calcium Electroporation
- Any patient who has been treated using Electrochemotherapy
- Patients must be mentally capable of understanding the information given
- Patients must give written informed consent.
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04929912
Related Trials
Frailty in Patients With Gastrointestinal Cancer Who Are Undergoing Major Surgery
NCT056943382 locations
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
NCT013134421 location
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT031909411 location
BOLSTER: Learning New Skills to Thrive
NCT069368782 locations
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT0659669462 locations